Diadem Presents Clinical Data and Commercialization Plans for Its AlzoSure® Prognostic Biomarker Test at 2020 Alzheimer s Disease International Conference Blood-Based AlzoSure Assay Has Potential to Transform Management of Alzheimer s Disease by Identifying Patients Early in the Disease Process
News provided by
Share this article
Share this article
MILAN, Dec. 11, 2020 /PRNewswire/ Diadem srl, a company developing the first blood-based test for the early prediction of Alzheimer s disease (AD), today reported that it hosted a Symposium on its prognostic biomarker test at the 34
th Annual Conference of Alzheimer s Disease International (ADI). Diadem presented early clinical data for its AlzoSure
® Predict assay in the Symposium, outlined initial commercialization plans and hosted an expert panel. To view a replay of the Symposium, click here